Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AUROVELA 1.5/30 vs AFIRMELLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combined estrogen-progestin contraceptive: ethinyl estradiol suppresses gonadotropin (FSH, LH) release via negative feedback on pituitary; norethindrone acetate inhibits ovulation by suppressing LH surge, altering cervical mucus and endometrial lining.
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.
Prevention of pregnancy,Treatment of moderate acne vulgaris in females at least 15 years old who have achieved menarche and desire contraception,Off-label: menstrual cycle regulation, dysmenorrhea, endometriosis-associated pain
Prevention of pregnancy (FDA-approved)
One tablet (1.5 mg norethindrone acetate, 30 mcg ethinyl estradiol) orally once daily at the same time each day for 21 days, followed by 7 days of placebo.
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
Norethindrone: 8-10 hours; Ethinyl estradiol: 13-27 hours. Steady-state achieved within 5-7 days.
Terminal elimination half-life: 12–15 hours. Steady-state achieved within 5 days with Q12H dosing.
Ethinyl estradiol undergoes hepatic CYP3A4 metabolism. Norethindrone acetate is deacetylated to norethindrone, which is metabolized primarily via reduction and conjugation (CYP3A4 minor role).
Ethinyl estradiol undergoes first-pass metabolism in gut and liver via CYP3A4, with conjugation to sulfate and glucuronide. Levonorgestrel is metabolized primarily by CYP3A4 to reduced and hydroxylated metabolites, then conjugated.
Renal (25% norethindrone metabolites, 5% ethinyl estradiol metabolites) and fecal (60% norethindrone, 30% ethinyl estradiol); <1% unchanged drug in urine.
Renal: 50% as unchanged drug and metabolites; fecal: 40% as metabolites; biliary: ~10% as glucuronide conjugates.
Norethindrone: 75% bound to albumin and SHBG; Ethinyl estradiol: 95-98% bound to albumin.
~99% bound to serum albumin and sex hormone-binding globulin.
Norethindrone: 3.5-4.5 L/kg; Ethinyl estradiol: 3-5 L/kg; reflects extensive tissue distribution.
2.8 L/kg (apparent Vd), indicating extensive tissue distribution.
Norethindrone: 65% (first-pass effect); Ethinyl estradiol: 40-50% (first-pass effect).
Oral: ~70% due to first-pass metabolism.
No specific dose adjustment recommended. Use with caution in severe renal impairment (GFR < 30 m L/min) due to potential fluid retention.
No dose adjustment required for mild to moderate renal impairment. Not recommended for use in end-stage renal disease.
Contraindicated in Child-Pugh class B or C (moderate to severe hepatic impairment). For Child-Pugh class A, use with caution, monitor liver function.
Contraindicated in acute hepatic disease or severe (Child-Pugh C) hepatic impairment. Use with caution in mild to moderate hepatic impairment; monitor liver function.
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily).
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily) based on adult clinical trials.
Not indicated for use in postmenopausal women.
Not indicated for use in postmenopausal women; no specific dose adjustment required in healthy elderly, but limited data available.
Cigarette smoking increases risk of serious cardiovascular events from combined hormonal contraceptives (CHCs). Risk increases with age and number of cigarettes smoked. Women over 35 who smoke should not use CHCs.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women over 35) and with heavy smoking (15+ cigarettes/day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Increased risk of thromboembolic events, myocardial infarction, stroke, hepatic neoplasia, gallbladder disease, hypertension. Should be discontinued if jaundice, visual disturbances, or migraine develops. Monitor blood pressure, glucose, and lipids in at-risk patients.
Thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Cigarette smoking (increases cardiovascular risk),Hypertension (especially in women with renal disease or migraines),Gallbladder disease,Hepatic neoplasia (benign and malignant),Carbohydrate and lipid metabolism effects,Ocular lesions (retinal thrombosis),Depressed mood or depression,Uterine bleeding irregularities,Reduced efficacy with hepatic enzyme inducers
Thrombophlebitis or thromboembolic disorders, history of deep vein thrombosis or pulmonary embolism, cerebrovascular or coronary artery disease, known or suspected breast cancer, endometrial cancer or other estrogen-dependent neoplasia, undiagnosed abnormal genital bleeding, cholestatic jaundice of pregnancy or jaundice with prior pill use, hepatic adenomas or carcinomas, known or suspected pregnancy, hypersensitivity to any component, and women over 35 who smoke.
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast cancer, endometrial cancer, or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma (current or history),Known or suspected pregnancy,Hypersensitivity to any component of the product,Heavy smoking (≥15 cigarettes/day) in women over 35
Grapefruit juice may increase estrogen levels; avoid large quantities. No other significant food interactions. Take with food if nausea occurs.
Grapefruit juice may increase ethinyl estradiol levels; avoid large quantities. No significant food restrictions. Administer with food if GI upset occurs.
AUROVELA 1.5/30 (ethinyl estradiol 30 mcg, levonorgestrel 1.5 mg) is contraindicated in pregnancy. First trimester exposure is not associated with a significant increase in major malformations; however, hormonal contraceptives should be discontinued if pregnancy is suspected. Second and third trimester exposure may increase risks of fetal genital tract abnormalities (e.g., hypospadias with progestins) and potential long-term effects, though data are limited due to contraindication.
Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defects). Second and third trimesters: increased risk of fetal growth restriction, preterm birth, and neonatal respiratory distress. Postnatal: possible long-term developmental effects.
AUROVELA 1.5/30 is excreted in breast milk in small amounts. Ethinyl estradiol M/P ratio approximately 0.4; levonorgestrel M/P ratio approximately 0.6. The combination may reduce milk production and composition, especially in early postpartum. Use is not recommended during breastfeeding unless no alternative; if used, monitor infant for jaundice and weight gain.
Contraindicated during breastfeeding. Small amounts of ethinyl estradiol and norethindrone are excreted in breast milk; M/P ratio not well defined. Potential for adverse effects on infant (e.g., jaundice, breast enlargement). May reduce milk production and quality.
AUROVELA 1.5/30 is contraindicated in pregnancy; no dose adjustments apply. Pharmacokinetic changes in pregnancy (e.g., increased hepatic metabolism, increased plasma volume) are not relevant as use is contraindicated. Discontinue immediately if pregnancy occurs.
Contraindicated in pregnancy; no dose adjustment recommended. If exposure occurs, immediate discontinuation is required. No pharmacokinetic data support safe use; avoid use entirely.
AUROVELA 1.5/30 is a monophasic oral contraceptive containing norethindrone acetate 1.5 mg and ethinyl estradiol 30 mcg. It is indicated for contraception and management of menstrual disorders. Note increased thrombotic risk in smokers over 35. Adjust dosing if patient is on enzyme-inducing antiepileptics or rifampin. Breakthrough bleeding common in first 3 cycles.
Afirmelle (levonorgestrel/ethinyl estradiol) is a combined oral contraceptive. Counsel patients to take at the same time daily to maintain consistent hormone levels. Use back-up contraception if a dose is missed. Monitor for signs of thromboembolism, especially in smokers over 35. Advise that certain antibiotics (e.g., rifampin) and anticonvulsants (e.g., phenytoin) may reduce efficacy. Consider progestin-only pill if contraindications to estrogen exist.
Take one tablet daily at same time, with or without food.,If missed pill, follow package instructions; use backup contraception if needed.,Common side effects: nausea, breast tenderness, breakthrough bleeding; usually subside.,Monitor for symptoms of thrombosis: leg pain, swelling, chest pain, shortness of breath.,No protection against STIs; use condoms for prevention.,Inform your doctor if you smoke, have migraines with aura, or history of blood clots.
Take one pill at the same time every day, even if you don't have sex.,If you miss a pill, follow the instructions in the package insert or ask your healthcare provider.,Use a backup method (like condoms) if you start late or miss pills.,This medication does not protect against HIV or other sexually transmitted infections.,Common side effects include nausea, breast tenderness, and breakthrough bleeding.,Seek medical help if you have symptoms of a blood clot: sudden chest pain, leg swelling, or shortness of breath.,Smoking while on this pill increases your risk of serious cardiovascular events.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AUROVELA 1.5/30 vs AFIRMELLE, answered by our medical review team.
AUROVELA 1.5/30 is a Oral Contraceptive that works by Combined estrogen-progestin contraceptive: ethinyl estradiol suppresses gonadotropin (FSH, LH) release via negative feedback on pituitary; norethindrone acetate inhibits ovulation by suppressing LH surge, altering cervical mucus and endometrial lining.. AFIRMELLE is a Combined Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AUROVELA 1.5/30 and AFIRMELLE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AUROVELA 1.5/30 is: One tablet (1.5 mg norethindrone acetate, 30 mcg ethinyl estradiol) orally once daily at the same time each day for 21 days, followed by 7 days of placebo.. The standard adult dose of AFIRMELLE is: One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AUROVELA 1.5/30 and AFIRMELLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AUROVELA 1.5/30 is classified as Category C. AUROVELA 1.5/30 (ethinyl estradiol 30 mcg, levonorgestrel 1.5 mg) is contraindicated in pregnancy. First trimester exposure is not associated with a significant increase in major m. AFIRMELLE is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.